SMMT - Summit Therapeutics Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
SMMT price evolution
SMMT
| (in millions $) | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 | 9 Aug 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $215.01 | |||
| Short term investments | $12.49 | |||
| Net receivables | $0.95 | $0.94 | $0.85 | $0.81 |
| Inventory | ||||
| Total current assets | $328.79 | $163.26 | $189.71 | $227.5 |
| Long term investments | $9.87 | |||
| Property, plant & equipment | $8.94 | $9.55 | $6.06 | $0.23 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $341.86 | $176.78 | $202.95 | $237.37 |
| Current liabilities | ||||
| Accounts payable | $3.34 | $6.37 | $2.67 | $0.99 |
| Deferred revenue | ||||
| Short long term debt | $2.93 | |||
| Total current liabilities | $140.17 | $23.44 | $20.41 | $11.93 |
| Long term debt | $100 | $100 | $104.33 | |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $146.78 | $132.57 | $125.26 | $117.77 |
| Shareholders' equity | ||||
| Retained earnings | -$1097.12 | -$1036.73 | -$993.26 | -$935.42 |
| Other shareholder equity | -$2.5 | -$2.45 | -$2.45 | -$2.32 |
| Total shareholder equity | $119.6 | |||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $348.61 | $71.79 | $66.42 | |
| Short term investments | $7.76 | |||
| Net receivables | $0.85 | $6.12 | $17.16 | $10.19 |
| Inventory | ||||
| Total current assets | $189.71 | $656.71 | $97.31 | $87.67 |
| Long term investments | $7.46 | |||
| Property, plant & equipment | $6.06 | $5.08 | $3.48 | $1.28 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $202.95 | $664.17 | $113.37 | $102.5 |
| Current liabilities | ||||
| Accounts payable | $2.67 | $0.35 | $4.37 | $6.14 |
| Deferred revenue | ||||
| Short long term debt | $21.46 | |||
| Total current liabilities | $20.41 | $38.78 | $25.62 | $19.89 |
| Long term debt | $100 | $494.54 | ||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $125.26 | $537.51 | $30.09 | $23.05 |
| Shareholders' equity | ||||
| Retained earnings | -$993.26 | -$378.33 | -$299.55 | -$210.95 |
| Other shareholder equity | -$2.45 | -$1.89 | -$2.2 | -$3.79 |
| Total shareholder equity | $126.65 | $83.28 | $79.45 | |
| (in millions $) | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 | 9 Aug 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $9.45 | |||
| Selling, general & administrative | $6.32 | |||
| Total operating expenses | $15.79 | |||
| Operating income | -$15.79 | |||
| Income from continuing operations | ||||
| EBIT | -$15.79 | |||
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$14.72 | |||
| Income (for common shares) | -$14.72 | |||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.7 | $1.81 | $0.86 | |
| Cost of revenue | ||||
| Gross Profit | $1.81 | $0.86 | ||
| Operating activities | ||||
| Research & development | $85.35 | $53.27 | ||
| Selling, general & administrative | $23.61 | $19.23 | ||
| Total operating expenses | $609.6 | $64.33 | $88 | $53.19 |
| Operating income | -$86.19 | -$52.33 | ||
| Income from continuing operations | ||||
| EBIT | -$86.19 | -$52.33 | ||
| Income tax expense | -$0.21 | |||
| Interest expense | -$7 | -$0.28 | -$0.26 | |
| Net income | ||||
| Net income | -$614.9 | -$78.78 | -$88.6 | -$52.7 |
| Income (for common shares) | -$88.6 | -$52.7 | ||
| (in millions $) | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 | 9 Aug 2023 |
|---|---|---|---|---|
| Net income | -$14.72 | |||
| Operating activities | ||||
| Depreciation | $0.47 | |||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$29.27 | |||
| Investing activities | ||||
| Capital expenditures | -$0.02 | |||
| Investments | ||||
| Total cash flows from investing | -$180.21 | $19.87 | -$587.77 | $0.21 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | -$120.24 | |||
| Total cash flows from financing | $200.7 | $0.48 | $86.51 | -$0.08 |
| Effect of exchange rate | -$0.02 | -$0.04 | $0.84 | |
| Change in cash and equivalents | -$42.67 | -$9.81 | -$577.18 | $215.01 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Net income | -$88.6 | -$52.7 | ||
| Operating activities | ||||
| Depreciation | $2.46 | $2 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$72.59 | -$48.11 | ||
| Investing activities | ||||
| Capital expenditures | -$0.31 | -$0.42 | ||
| Investments | ||||
| Total cash flows from investing | -$587.77 | -$0.62 | -$0.31 | -$0.42 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $86.51 | $620.24 | $77.92 | $50.55 |
| Effect of exchange rate | $0.84 | -$1.22 | $0.35 | $0.56 |
| Change in cash and equivalents | -$577.18 | $576.82 | $5.37 | $2.58 |
News
Fundamentals
| Market cap | $8.89B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 724.32M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.35 |
| Quick ratio | N/A |